Skip to main content
. 2019 Jul 9;10:199–208. doi: 10.2147/JBM.S202286

Figure 1.

Figure 1

(A) Overall survival with ibrutinib versus conventional second-line therapy; (B) progression-free survival with ibrutinib versus conventional second-line therapy; (C) overall survival with ibrutinib versus conventional first-line therapy; (D) progression-free survival with ibrutinib versus conventional first-line therapy.